Site icon AJKD Blog

Pemetrexed Nephrotoxicity

eAJKD Video Interview: Kidney Tubular Toxicity of Maintenance Pemetrexed Therapy

Featuring

Kenar Jhaveri, MD, eAJKD Blog Editor

and

Authors:

Ilya Glezerman, MD
Renal Service, Attending Nephrologist
Memorial Sloan Kettering Cancer Center

Surya Seshan, MD
Chief of Renal Pathology, Professor of Pathology
Weill Cornell Medical Center

Pemetrexed is an antifolate agent approved for the treatment of advanced lung cancer.A recent publication in American Journal of Kidney Diseases discusses potential nephrotoxicity of this drug. Kidney biopsy specimens showed tubulointerstitial injury with tubular simplification, shrinkage, loss of brush border, and tubular atrophy in a more advanced case.  eAJKD did an exclusive video blog with the authors Dr. Ilya Glezerman( Renal service, Memorial Sloan Kettering Cancer Center, NY) and Dr.Surya Seshan( Chief of Renal Pathology, Professor of Pathology, Weill Cornell Medical Center, NY). Check out the complete article at AJKD.

Exit mobile version